Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05208762 · ClinicalTrials.gov registry record · Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
A Phase 1 study of Endometrial Cancer and Gastric Cancer, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 714
- Enrollment target
- 20
- Study locations
NCT05208762 is a Phase 1 study of Endometrial Cancer and Gastric Cancer that is actively recruiting participants, run by Seagen, a wholly owned subsidiary of Pfizer. The registered enrollment target is 714 participants, above the 520-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (37% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT05208762, a Phase 1 study of Endometrial Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Seagen, a wholly owned subsidiary of Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 714 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have five parts. Parts A and B of the study will find out how much PF-08046054/SGN- PDL1V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe PF-08046054/SGN-PDL1V is and if it works to treat solid tumor cancers. In Part D and E, participants will be given PF-08046054/SGN-PDL1V with pembrolizumab to find out how safe this combination is and if it works to treat solid tumor cancers.
Conditions Studied
Interventions
- DRUG pembrolizumab
- DRUG PF-08046054
Study Locations (20)
Texas
- University of Texas Southwestern Medical Center - Simmons Cancer Center - Dallas
- UT Southwestern Medical Center - Redbird - Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital - Dallas
- University of Texas Southwestern Medical Center - William P. Clements, Jr., University Hospital - Dallas
- University Of Texas Southwestern Medical Center - Dallas
- UT Southwestern - Simmons Cancer Center - Fort Worth - Fort Worth
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services - Houston
- The University of Texas MD Anderson Cancer Center - Houston
Alabama
- University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham, IDS Pharmacy - Birmingham
- University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham - Birmingham
California
- Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
- UC Irvine Health - Chao Family Comprehensive Cancer Center - Orange
- University of California Davis Comprehensive Cancer Center - Sacramento
- University of California, Davis Medical Center - Sacramento
Michigan
- Karmanos Cancer Institute - Detroit
- Karmanos Cancer Institute - Farmington Hills
Iowa
- University of Iowa - Iowa City
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 714 participants |
| Start Date | 2022-10-25 |
| Est. Completion | 2029-01-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05208762
The ClinicalTrials.gov registry entry for NCT05208762 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 714 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 520-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (37% higher). The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.
NCT05208762 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Texas, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT05208762 about?
NCT05208762 is a clinical study titled "A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors". This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tum...
What is the current status of trial NCT05208762?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 714 participants. The study started on 2022-10-25. Estimated completion is 2029-01-04.
What conditions does trial NCT05208762 study?
This clinical trial studies the following conditions: Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma, Carcinoma, Non-Small Cell Lung, Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT05208762?
The interventions under investigation include: pembrolizumab (DRUG), PF-08046054 (DRUG).
Who is sponsoring clinical trial NCT05208762?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05208762 being conducted?
This trial has 20 study locations across Alabama, California, Iowa, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.